Supreme Court exposes GlaxoSmithKline to Humana's Avandia-spending claims

The U.S. Supreme Court declined to consider an appeal from GlaxoSmithKline ($GSK) in a fight over Humana's spending on the company's disgraced diabetes drug Avandia. The ruling not only opens GSK to the Humana suit, which applies to its Medicare Advantage plans, but also to potential lawsuits from other insurers. Report

Suggested Articles

Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.